More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$460737990
EPS
1
P/E ratio
19.4
Price to sales
6.4
Dividend yield
--
Beta
1.263409
Previous close
$21.29
Today's open
$21.28
Day's range
$21.15 - $22.60
52 week range
$19.20 - $39.71
show more
CEO
Jason A. Okazaki
Employees
73
Headquarters
South San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
20477244
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Assembly Biosciences, Inc. (ASMB) Presents at UBS Global Biopharma Conference 2026 Transcript
Assembly Biosciences, Inc. ( ASMB ) UBS Global Biopharma Conference 2026 November 17, 2026 7:00 AM EST Company Participants Jason Okazaki - CEO, President & Director Anuj Gaggar - Chief Medical Officer Katie Kitrinos - Senior VP of Preclinical Research & Development Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. Welcome to UBS Biopharma Conference in London.
Seeking Alpha • Nov 17, 2026

Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –
GlobeNewsWire • Nov 12, 2026

Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $0.72 per share a year ago.
Zacks Investment Research • Nov 12, 2026

Assembly Biosciences to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at the following upcoming investor conferences in November:
GlobeNewsWire • Nov 2, 2026

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –
GlobeNewsWire • Oct 29, 2026

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
GlobeNewsWire • Oct 5, 2026

New Strong Buy Stocks for September 17th
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
Zacks Investment Research • Sep 17, 2026

Best Momentum Stocks to Buy for September 17th
MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
Zacks Investment Research • Sep 17, 2026

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.
GlobeNewsWire • Sep 10, 2026

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Zacks Investment Research • Sep 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Assembly Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.